Tysabri Usage Restrictions Likely To Remain Stable As FDA Considers REMS Modifications

While the label of Biogen Idec/Elan's multiple sclerosis drug is expected to be changed to reflect a suspected link between JC-virus and the viral brain infection progressive multifocal leukoencephalopathy, that is unlikely to lead to a new contraindication.